American Heart Journal
Volume 150, Issue 4 , Pages 627-642 , October 2005

Design and methodology of the Occluded Artery Trial (OAT)

Received 15 December 2004 ,Accepted 7 July 2005.

References 

  1. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol. 2000;36:2056–2063
  2. LATE Investigators . Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet. 1993;342:759–766
  3. EMERAS (Estudio Multicentro Estreptoquinasa Republicas de America del Sur) Collaborative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet. 1993;342:767–772
  4. Bertrand ME, Lefevbre JM, Rousseau MF, et al. Coronary arteriography in acute transmural myocardial infarction. Am Heart J. 1979;97:61
  5. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897–902
  6. Kerensky RA, Wade M, Deedwania P, et al. Revisiting the culprit lesion in non–Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol. 2002;39:1456–1463
  7. Ferry DR, O'Rourke RA, Blaustein AS, et al. Design and baseline characteristics of the Veterans Affairs Non–Q-Wave Infarction Strategies In-Hospital (VANQWISH) trial. VANQWISH Trial Research Investigators. J Am Coll Cardiol. 1998;31:312–320
  8. Ryan TJ, Antman EM, Brooks NH, et al. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1999;34:890–911
  9. Sadanandan S, Buller C, Menon V, et al. The late open artery hypothesis—a decade later. Am Heart J. 2001;142:411–421
  10. Berger AK, Edris EW, Breall JA, et al. Resource use and quality of care for Medicare patients with acute myocardial infarction in Maryland and the District of Columbia: analysis of data from the Cooperative Cardiovascular Project. Am Heart J. 1998;135:349–356
  11. Guadagnoli E, Hauptman PJ, Ayanian JZ, et al. Variation in the use of cardiac procedures after acute myocardial infarction. N Engl J Med. 1995;333:573–578
  12. Pilote L, Califf RM, Sapp S, et al. Regional variation across the United States in the management of acute myocardial infarction. N Engl J Med. 1995;333:565–572
  13. Fox KA, Goodman SG, Anderson FA, et al. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. Eur Heart J. 2003;24:1414–1424
  14. Van de Werf F, Topol EJ, Lee KL, et al. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. JAMA. 1995;273:1586–1591
  15. Rouleau JL, Moye LA, Pfeffer MA, et al. A comparison of management patterns after acute myocardial infarction in Canada and the United States. N Engl J Med. 1993;328:784–799
  16. White HD, Cross DB, Elliott JM, et al. Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation. 1994;89:61–67
  17. Puma JA, Sketch MH, Thompson TD, et al. Support for the open-artery hypothesis in survivors of acute myocardial infarction: analysis of 11,228 patients treated with thrombolytic therapy. Am J Cardiol. 1999;83:482–487
  18. Franzosi MG, Santoro E, De Vita C, et al. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction. Circulation. 1998;98:2659–2665
  19. Baigent C, Collins R, Appleby P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ. 1998;316:1337–1343
  20. Califf RM, Topol EJ, Gersh BJ. From myocardial salvage to patient salvage in acute myocardial infarction: the role of reperfusion therapy. J Am Coll Cardiol. 1989;14:1382–1388
  21. Hillis LD, Lange RA. Time for a randomized trial of the “open artery hypothesis” in survivors of acute myocardial infarction. Am J Cardiol. 1992;69:1359–1360
  22. Kim CB, Braunwald E. Potential benefits of late reperfusion of infarcted myocardium. The open artery hypothesis. Circulation. 1993;88:2426–2436
  23. Hochman JS. Has the time come to seek and open all occluded infarct related arteries after myocardial infarction?. J Am Coll Cardiol. 1996;28:846–848
  24. White HD. Should all occluded infarct-related arteries be opened?. Eur Heart J. 1997;18:1207–1209
  25. Mathew V, Gersh BJ. To open or not to open: that remains the question. Eur Heart J. 2004;25:2177–2179
  26. Topol EJ, Califf RM, Grines CL, et al. A randomized trial of late reperfusion therapy for acute myocardial infarction. Circulation. 1992;85:2090–2099
  27. Dzavik V, Beanlands DS, Davies RF, et al. Effects of late percutaneous transluminal coronary angioplasty of an occluded infarct-related coronary artery on left ventricular function in patients with a recent (6 weeks) Q-wave acute myocardial infarction. Am J Cardiol. 1994;73:856–861
  28. Horie H, Takahashi M, Minai K, et al. Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty. Circulation. 1998;98:2377–2382
  29. Yousef ZR, Redwood SR, Bucknall CA, et al. A randomized trial of delayed intervention after myocardial infarction: clinical end point and echocardiographic data from the Open Artery Trial. Circulation. 2000;102(II Suppl):II755
  30. Steg PG, Thuaire C, Himbert D, et al. DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. Eur Heart J. 2004;25:2187–2194
  31. Zeymer U, Vogt A, Zahn R, et al. Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention: results of the primary PCI registry of the ALKK. Eur Heart J. 2004;25:322–328
  32. Williams DO, Borer J, Braunwald E, et al. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI Thrombolysis in Myocardial Infarction trial. Circulation. 1986;73:338–346
  33. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes. Circulation. 2003;108:1682–1687
  34. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–2420
  35. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Implications of recent clinical trials for the National Cholesterol Program Adult Treatment Panel III Guidelines. NGC:3746. Available online at http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf.
  36. ACC/AHA Guidelines for the management of patients with ST-elevation myocardial infarction. Available online at http://www.acc.org/clinical/guidelines/stemi/index.pdf.
  37. Heart failure in adults. NGC:3514. Available online at http://www.guideline.gov/summary/summary.aspx?doc_id=4927&nbr=3514&string=heart+AND+failure+AND+guideline+AND+ahrq.
  38. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult. Circulation. 2001;104:2996–3007
  39. Dzavik V, Carere RG, Teo KK, et al. An open design, multicentre, randomized trial of percutaneous transluminal coronary angioplasty versus stenting, with a heparin-coated stent, of totally occluded coronary arteries: rationale, trial design and baseline patient characteristics. Total Occlusion Study of Canada (TOSCA) investigators. Can J Cardiol. 1998;14:825–832
  40. Lamas GA, Flaker GC, Mitchell G, et al. Effect of infarct artery patency on prognosis after acute myocardial infarction. Circulation. 1995;92:1101–1109
  41. Peto R, Pike MC, Armitage N, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer. 1977;35:1–39
  42. Schoenfeld DA. Sample size formula for the proportional hazards regression model. Biometrics. 1983;39:499–503
  43. Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics. 1986;42:507–519
  44. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  45. Thompson BW, Knatterud GL. Interim monitoring plans to simultaneously evaluate a composite end point and a severe adverse event that is part of the composite end point. Control Clin Trials. 2001;22:32S
  46. Bonferroni CE. Il calcolo delle assicurazioni su gruppi di teste. In: Studi in Onore del Professore Salvatore Ortu Carboni. Rome: Italy; 1935;p. 13–60
  47. Lan KK, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659
  48. Reboussin DM, DeMets DL, Kim K, et al. Programs for computing group sequential bounds using the Lan-DeMets method. Technical report no. 60 University of Wisconsin Department of Biostatistics, Madison, 1992.
  49. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187–220

 Funding Source: National Heart, Lung, and Blood Institute grant numbers U01 HL62509, U01 HL62257-05, and U01 HL62511.

PII: S0002-8703(05)00696-4

doi: 10.1016/j.ahj.2005.07.002

American Heart Journal
Volume 150, Issue 4 , Pages 627-642 , October 2005

Article Tools

* Image Usage & Resolution